Article

12-month results of two ranibizumab trials show promise

The 12-month results of two randomized clinical trials of ranibizumab (Lucentis, Genentech) indicate that the drug shows encouraging signs of activity against vascular endothelial growth factor (VEGF) in age-related macular degeneration (AMD), reported Jeffrey Heier, MD, Friday at the retina subspecialty day at the American Academy of Ophthalmology

Chicago-The 12-month results of two randomized clinical trials of ranibizumab (Lucentis, Genentech) indicate that the drug shows encouraging signs of activity against vascular endothelial growth factor (VEGF) in age-related macular degeneration (AMD), reported Jeffrey Heier, MD, Friday at the retina subspecialty day at the American Academy of Ophthalmology.

The RhuFab V Ocular Treatment Combining the Use of Visudyne to Evaluate Safety Study (FOCUS) is a phase I/II trial of the safety, tolerability, and efficacy of ranibizumab (0.5 mg) combined with photodynamic therapy (PDT) (verteporfin; Visudyne, Novartis/QLT) compared with PDT alone in patients with subfoveal predominantly classic choroidal neovascularization in AMD. All patients received PDT and were then randomized to ranibizumab (0.3 or 0 mg) injections or sham injection for 24 injections over 2 years.

“The 12-month results indicated that over 90% of the patients who received combination therapy reached the primary study endpoint of loss of fewer than 15 letters of visual acuity compared with 68% of patients who received PDT alone,” said Dr. Heier, clinical instructor in ophthalmology, Tuft School of Medicine and Harvard Medical School, Boston.

Importantly, 24% of the patients who received combination therapy had an improvement of three or more lines of vision versus 5% of those who received PDT alone.

The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) Study is a phase III trial of patients with subfoveal minimally classic/occult choroidal neovascularization secondary to AMD. Patients received either sham injections or ranibizumab (0.3 or 0.5 mg) injections for 24 treatments over 2 years. The 12-month results indicated that “there was a dramatic difference between the ranibizumab patients, 95% of whom lost fewer than 15 letters of vision compared with about 62% of the control patients,” Dr. Heier reported.

“Patients who received ranibizumab were far less likely to loss vision and far more likely to gain vision. There was a low rate of serious ocular adverse events and no apparent safety concerns,” he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.